Brief: Redhill's Opaganib Receives FDA Rare Pediatric Disease Designation For Neuroblastoma In Addition To Current Orphan Drug Designation
09/06/2026 12:02
BRIEF-Redhill's Opaganib Receives FDA Rare Pediatric Disease Designation For Neuroblastoma In Addition To Current Orphan Drug Designation June 9 (Reuters) - Redhill Biopharma Ltd 2RHy.F:
REDHILL'S OPAGANIB RECEIVES FDA RARE PEDIATRIC DISEASE DESIGNATION FOR NEUROBLASTOMA IN ADDITION TO CURRENT ORPHAN DRUG DESIGNATION
REDHILL'S OPAGANIB RECEIVES FDA RARE PEDIATRIC DISEASE DESIGNATION FOR NEUROBLASTOMA IN ADDITION TO CURRENT ORPHAN DRUG DESIGNATION
Source text: ID:nPn4fFBL3a
Further company coverage: [2RHy.F]